Forecasting The Future: 4 Analyst Projections For Gritstone Bio
During the last three months, 4 analysts shared their evaluations of Gritstone Bio (NASDAQ:GRTS), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.25, a high estimate of $5.00, and a low estimate of $3.00. This current average has decreased by 22.73% from the previous average price target of $5.50.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Gritstone Bio among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Roy Buchanan | JMP Securities | Maintains | Market Outperform | $5.00 | $5.00 |
| Mayank Mamtani | B. Riley Securities | Lowers | Buy | $3.00 | $6.00 |
| Sean Lee | HC Wainwright & Co. | Lowers | Buy | $4.00 | $7.00 |
| Roy Buchanan | JMP Securities | Raises | Market Outperform | $5.00 | $4.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gritstone Bio. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gritstone Bio compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Gritstone Bio's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Gritstone Bio's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Gritstone Bio analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Gritstone Bio
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.
Breaking Down Gritstone Bio's Financial Performance
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Gritstone Bio's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -90.96%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gritstone Bio's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -82418.37%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gritstone Bio's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -122.72%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -25.64%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Gritstone Bio's debt-to-equity ratio is notably higher than the industry average. With a ratio of 7.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Understanding the Relevance of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.